In 2024, the home care settings and fitness/weight management facilities accounted for the largest share in the global GLP-1 agonists market
Furthermore, GLP-1R activation activates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway via G-protein coupled receptor subunits (Fletcher et al
These drugs have already changed the lives of many people with diabetes and those trying to lose weight
Additionally, the activation of GIP may amplify the weight loss and insulin secretion effects of GLP1 activation in the central nervous system and pancreas, respectively
Results from clinical trials suggest that such drugs could have potential for the treatment of asthma, which is one of the most chronic inflammatory pulmonary diseases in the world and often linked to both type 2 diabetes and obesity (Wu, Stokes Peebles)
doi: 10.1001/jama.2021.23619 102 WaddenTABaileyTSBillingsLKDaviesMFriasJPKorolevaAet al